Brief: Canbridge Announces Encouraging Development In Maralixibat/Livmarli In Rare Liver Disease
27/10/2022 03:35
Oct 26 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* CANBRIDGE ANNOUNCES ENCOURAGING DEVELOPMENT IN
MARALIXIBAT/LIVMARLI IN RARE LIVER DISEASE
* CANBRIDGE - CO'S PARTNER MIRUM PHARMACEUTICALS REPORTED
POSITIVE
TOPLINE DATA FROM ITS PHASE 3 MARCH STUDY EVALUATING SAFETY AND
EFFICACY OF LIVMARLI
Source text for Eikon: ID:nBwd8WYza
Further company coverage: 1228.HK
((Reuters.Brief@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares